# The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

> **NCT04447768** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 100 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04447768
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-03
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447768, "The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04447768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*